This press release was published on the Plasmacure website on July 7, 2025. It is published here with permission.
NIJMEGEN, The Netherlands – Plasmacure B.V., a Dutch MedTech innovator and developer of the PLASOMA cold plasma system for complex wound treatment, today announces a €6 million Series A investment from a strategic consortium led by U.S.-based Venture Medical, LLC. The consortium invests directly in Plasmacure. Venture Medical will also finance the regulatory and reimbursement pathways in the U.S. market, an effort expected to exceed $10 million.
The funding consortium also includes Dutch health insurer Coöperatie VGZ, impact investor Noaber, and Stichting Triade, alongside existing shareholders EIC Fund and Oost NL. This investment will enable Plasmacure to scale globally and advance the adoption of PLASOMA as a next-generation solution for complex wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers.
As global populations age and the prevalence of diabetes continues to rise, an estimated 5% of elderly individuals suffer from complex wounds, conditions that severely impact quality of life and often lead to amputation. Standard treatment approaches show limited effectiveness, contributing to wound chronicity and accounting for an estimated 2–4% of total healthcare expenditure. In a recent randomized controlled trial, PLASOMA demonstrated the ability to close up to 2.5 times more complex wounds than the current standard of care.
“We are deeply motivated by the needs of the millions living with hard-to-heal wounds,” said Bjorn Sprengers, CEO of Plasmacure. “With this investment and our new strategic partners, we are in a strong position to bring PLASOMA to more patients worldwide. Our vision is to transform wound care; to improve outcomes and to give patients back their mobility, dignity, and freedom. With PLASOMA, we aim to set a new global standard in the treatment of complex wounds.”
“We see PLASOMA as a transformative technology that redefines what’s possible in wound healing. By investing in Plasmacure and supporting its U.S. rollout, we are enabling clinicians to offer next generation care that is both innovative and accessible,” said John Schroeder, CEO of Venture Medical.
Martijn Kers, Director of Healthcare Policy and Innovation at Coöperatie VGZ, added:
“At VGZ, we are committed to meaningful care: care that demonstrably works and improves the quality of life for our members. Plasmacure is a prime example of this. Last year, we nominated Plasmacure for the VGZ Award: Healthcare Innovator of the Future, an initiative that recognizes and encourages promising healthcare startups. We see great potential in PLASOMA to significantly improve care for people with chronic wounds.”
Cold plasma is created by energizing gas molecules, producing a highly effective antimicrobial agent capable of eliminating even antibiotic-resistant bacteria. It also stimulates blood flow and cell regeneration. The PLASOMA pulser delivers controlled electric pulses to a disposable pad, generating cold plasma directly in the wound. This safely initiates multiple healing mechanisms, accelerating recovery and reducing the burden of chronic wounds.
About Plasmacure B.V.
Founded in 2014 in the Netherlands, Plasmacure B.V. leads the shift from conventional chronic wound management to high-impact technological solutions. Its flagship product, PLASOMA, applies cold plasma to accelerate healing in complex wounds, demonstrating up to 2.5 times greater effectiveness than standard care. Learn more at www.plasmacure.nl or www.plasmacure.nl/en/press
About Venture Medical, LLC
Venture Medical is a leading U.S.-based healthcare services company with over 15 years of experience in advanced wound care and healing. It operates as a master distributor, reseller, and digital solutions provider, serving healthcare manufacturers and end-users across biologics, diagnostics, DME, and capital equipment sectors. Learn more at www.venturemedical1.com.
About VGZ & the ‘Voorop in de Zorg’ Fund
VGZ is committed to helping future-proof healthcare and aims to be a leader in sustainable investing. Its ‘Voorop in Zorg’ fund supports this mission by investing 2.5% of VGZ’s capital in innovative companies that keep healthcare accessible and affordable. The fund focuses on (pre)seed and early-stage startups in Medtech, Healthtech, Digital Health Services, and data exchange. In addition to capital, VGZ provides healthcare expertise to accelerate growth with an ambition to improve care for all.